CG Oncology reposted this
We had a great ending to #ASCO24 earlier this week, advancing strides in #bladdercancer research and patient care where significant unmet needs persist. Thank you, Jason Broderick of Urology Times, for highlighting the encouraging results of our Phase 2 CORE-001 final study for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-#NMIBC). Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by principal investigator Roger Li, M.D., the combination of cretostimogene grenadenorepvec and pembrolizumab showed a sustained, high complete response (CR) rate of 54.3% (95% CI, 36.9%-70.8%) in the 35-patient intention-to-treat (ITT) population at 24 months. These results underscore cretostimogene’s potential as a novel oncolytic immunotherapy for bladder cancer patients. 📄 Read more about CORE-001 in Urology Times here: https://bit.ly/3Rbdycv If you were unable to connect with us during this year’s meeting, we encourage you to reach out to CG Oncology’s Medical Affairs at medicalaffairs@cgoncology.com. For more information about the study, CORE-001 (NCT04387461), and other studies sponsored by CG Oncology, visit www.clinicaltrials.gov or www.cgoncology.com. #CORE001 #UroOncology #CancerResearch #ClinicalResearch #PatientCare #ClinicalTrial #Therapeutics #DrugDevelopment #Immunotherapy #CGOncology #cretostimogene #UrologyTimes
